Through the joint collaboration, Seegene plans to accelerate development of its random access system on Hamilton's automated liquid handling platforms.
The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.
The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.
The partnership marks the first step in the company's plan to develop 100 new molecular diagnostics within the next two years.
Seegene will use its proprietary assay development technologies to create highly multiplexed tests for the Hologic Fusion platform.
The service — which Seegene plans to launch next year — boasts the specificity of fluorescently tagged probes at the cost of intercalating dyes.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
The worldwide collaboration agreement is for co-development of multiplex real-time PCR reagents for the BD Max molecular diagnostics platform.
Seegene will develop a menu of multiplex assay panels, initally in the area of infectious disease, for Qiagen's QIAsymphony RGQ molecular diagnostics platform.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.